Metformin: A review of potential mechanism and therapeutic utility beyond diabetes

S Dutta, RB Shah, S Singhal, SB Dutta… - Drug design …, 2023 - Taylor & Francis
Metformin has been designated as one of the most crucial first-line therapeutic agents in the
management of type 2 diabetes mellitus. Primarily being an antihyperglycemic agent …

Molecular mechanisms and signaling pathways involved in sertoli cell proliferation

SB Meroni, MN Galardo, G Rindone, A Gorga… - Frontiers in …, 2019 - frontiersin.org
Sertoli cells are somatic cells present in seminiferous tubules which have essential roles in
regulating spermatogenesis. Considering that each Sertoli cell is able to support a limited …

Metformin: A dual-role player in cancer treatment and prevention

MA Galal, M Al-Rimawi, A Hajeer, H Dahman… - International journal of …, 2024 - mdpi.com
Cancer continues to pose a significant global health challenge, as evidenced by the
increasing incidence rates and high mortality rates, despite the advancements made in …

Phase II clinical trial of metformin as a cancer stem cell–targeting agent in ovarian cancer

JR Brown, DK Chan, JJ Shank, KA Griffith, H Fan… - JCI …, 2020 - pmc.ncbi.nlm.nih.gov
BACKGROUND Epidemiologic studies suggest that metformin has antitumor effects.
Laboratory studies indicate metformin impacts cancer stem-like cells (CSCs). As part of a …

Metformin in cancer therapy: a new perspective for an old antidiabetic drug?

I Ben Sahra, Y Le Marchand-Brustel… - Molecular cancer …, 2010 - aacrjournals.org
Metformin is the most widely used antidiabetic drug in the world, and there is increasing
evidence of a potential efficacy of this agent as an anticancer drug. First, epidemiological …

Obesity, type 2 diabetes, and cancer: the insulin and IGF connection

DH Cohen, D LeRoith - Endocrine-related cancer, 2012 - erc.bioscientifica.com
Epidemiological studies suggest a positive association between obesity and type 2 diabetes
mellitus (T2D) with the risk of cancer and cancer-related mortality. Insulin resistance …

Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy

WY Shi, D **ao, L Wang, LH Dong, ZX Yan… - Cell death & …, 2012 - nature.com
Adenosine monophosphate-activated protein kinase (AMPK) acts as a major sensor of
cellular energy status in cancers and is critically involved in cell sensitivity to anticancer …

Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo

R Rattan, RP Graham, JL Maguire, S Giri, V Shridhar - Neoplasia, 2011 - Elsevier
Ovarian cancer is the most lethal gynecologic cancer in women. Its high mortality rate (68%)
reflects the fact that 75% of patients have extensive (> stage III) disease at diagnosis and …

Metformin inhibits melanoma development through autophagy and apoptosis mechanisms

T Tomic, T Botton, M Cerezo, G Robert, F Luciano… - Cell death & …, 2011 - nature.com
Metformin is the most widely used antidiabetic drug because of its proven efficacy and
limited secondary effects. Interestingly, recent studies have reported that metformin can …

Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer

S Giri, A Karakoti, RP Graham, JL Maguire, CM Reilly… - PloS one, 2013 - journals.plos.org
Ovarian cancer (OvCa) is the fifth most common cause of death from all cancers among
women in United Sates and the leading cause of death from gynecological malignancies …